4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 94 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $156 | +44.4% | 12,254 | +95.3% | 0.00% | +100.0% |
| Q1 2023 | $108 | -43.8% | 6,275 | -27.3% | 0.00% | -50.0% |
| Q4 2022 | $192 | -99.9% | 8,631 | -59.4% | 0.00% | 0.0% |
| Q3 2022 | $171,000 | +59.8% | 21,237 | +38.7% | 0.00% | +100.0% |
| Q2 2022 | $107,000 | -15.1% | 15,309 | +83.5% | 0.00% | 0.0% |
| Q1 2022 | $126,000 | -40.6% | 8,342 | -13.8% | 0.00% | 0.0% |
| Q4 2021 | $212,000 | -44.6% | 9,680 | -31.8% | 0.00% | -50.0% |
| Q3 2021 | $383,000 | +71.7% | 14,197 | +53.2% | 0.00% | +100.0% |
| Q2 2021 | $223,000 | -84.0% | 9,265 | -72.5% | 0.00% | -85.7% |
| Q4 2020 | $1,396,000 | – | 33,680 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |